AstraZeneca PLC (AZN.L)
AZN.L on London Stock Exchange
6,094.00GBp
12 Dec 2018
6,094.00GBp
12 Dec 2018
Change (% chg)
-10.00 (-0.16%)
-10.00 (-0.16%)
Prev Close
6,104.00
6,104.00
Open
6,141.00
6,141.00
Day's High
6,153.00
6,153.00
Day's Low
6,068.00
6,068.00
Volume
1,677,789
1,677,789
Avg. Vol
1,938,974
1,938,974
52-wk High
6,432.48
6,432.48
52-wk Low
4,544.50
4,544.50
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Sep '18 | 5,340.00 | 0.340 |
| Jun '18 | 5,155.00 | 0.276 | |
| Mar '18 | 5,178.00 | 0.268 | |
| FY 2017 | Dec '17 | 5,777.00 | 1.048 |
| Sep '17 | 6,232.00 | 0.541 | |
| Jun '17 | 5,051.00 | 0.376 | |
| Mar '17 | 5,405.00 | 0.424 | |
| FY 2016 | Dec '16 | 5,585.00 | 1.455 |
| Sep '16 | 5,699.00 | 0.801 | |
| Jun '16 | 5,603.00 | -0.002 | |
| Mar '16 | 6,115.00 | 0.511 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 11 | 6,528.69 | 7,145.00 | 6,063.00 | 6,026.04 |
| Quarter Ending Mar-19 | 3 | 5,444.51 | 5,480.00 | 5,426.52 | 5,532.73 |
| Year Ending Dec-18 | 26 | 22,109.00 | 23,072.80 | 20,634.00 | 22,080.60 |
| Year Ending Dec-19 | 26 | 23,580.90 | 25,602.00 | 21,662.00 | 23,637.30 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | 10 | 1.39 | 1.72 | 0.90 | 0.97 |
| Quarter Ending Mar-19 | 3 | 0.84 | 0.97 | 0.77 | -- |
| Year Ending Dec-18 | 27 | 3.41 | 3.60 | 3.28 | 3.68 |
| Year Ending Dec-19 | 27 | 3.84 | 4.50 | 3.21 | 4.18 |
| LT Growth Rate (%) | 3 | 7.57 | 13.20 | 4.51 | 3.88 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | 22.12 | 31.13 | 34.39 | |
| P/E High - Last 5 Yrs. | 72.73 | 40.59 | 46.24 | |
| P/E Low - Last 5 Yrs. | 9.58 | 23.99 | 24.59 | |
| Beta | 1.04 | 0.91 | 0.91 | |
| Price to Sales (TTM) | 3.94 | 4.00 | 6.22 | |
| Price to Book (MRQ) | 6.27 | 5.02 | 5.20 | |
| Price to Tangible Book (MRQ) | -- | 5.76 | 6.74 | |
| Price to Cash Flow (TTM) | 13.70 | 23.20 | 24.17 | |
| % Owned Institutions | -- | 0.95 | 1.78 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.55 | 1.44 | |
| Dividend Yield - 5 Year Avg | 5.55 | 1.56 | 1.46 | |
| Dividend 5 Year Growth Rate | 4.86 | 4.21 | 4.94 | |
| Payout Ratio(TTM) | 62.12 | 45.68 | 42.49 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -9.85 | 2.33 | 8.17 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -9.65 | 4.80 | 6.50 | |
| Sales - 5 Yr. Growth Rate | -7.29 | 10.00 | 10.44 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 15,985.23 | 17.26 | 23.08 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 74.09 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -17.55 | 9.88 | 10.49 | |
| Capital Spending - 5 Yr. Growth Rate | 12.28 | 15.23 | 14.58 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 0.73 | 2.20 | 2.28 |
| Current Ratio (MRQ) | 0.91 | 3.02 | 3.10 |
| LT Debt to Equity (MRQ) | 122.99 | 8.89 | 11.49 |
| Total Debt to Equity (MRQ) | 144.47 | 12.69 | 16.03 |
| Interest Coverage (TTM) | 4.61 | 35.18 | 30.57 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 82.88 | 54.41 | 54.44 | |
| Gross Margin - 5 Yr. Avg. | 80.69 | 51.86 | 52.36 | |
| EBITD Margin (TTM) | 38.95 | -- | -- | |
| EBITD - 5 Yr. Avg | 31.99 | 18.41 | 13.16 | |
| Operating Margin (TTM) | 24.85 | 14.42 | 6.07 | |
| Operating Margin - 5 Yr. Avg. | 17.97 | 14.55 | 8.47 | |
| Pre-Tax Margin (TTM) | 18.09 | 14.96 | 7.02 | |
| Pre-Tax Margin - 5 Yr. Avg. | 14.67 | 14.97 | 8.71 | |
| Net Profit Margin (TTM) | 17.34 | 11.16 | 3.12 | |
| Net Profit Margin - 5 Yr. Avg. | 12.74 | 11.23 | 4.91 | |
| Effective Tax Rate (TTM) | 4.14 | 23.45 | 23.26 | |
| Effective Tax Rate - 5 Yr. Avg. | 13.16 | 23.65 | 23.83 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 278,767 | 997,016,667 | 873,056,423 | |
| Net Income/Employee (TTM) | 48,342 | 118,233,002 | 103,484,349 | |
| Receivable Turnover (TTM) | 4.36 | 5.82 | 5.80 | |
| Inventory Turnover (TTM) | 1.40 | 2.68 | 3.56 | |
| Asset Turnover (TTM) | 0.34 | 0.99 | 0.95 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | 5.82 | 11.98 | 11.45 | |
| Return on Assets - 5 Yr. Avg. | 5.71 | 13.28 | 12.50 | |
| Return on Investment (TTM) | 7.86 | 15.55 | 14.96 | |
| Return on Investment - 5 Yr. Avg. | 7.89 | 17.28 | 16.23 | |
| Return on Equity (TTM) | 28.47 | 16.92 | 16.52 | |
| Return on Equity - 5 Yr. Avg. | 15.71 | 18.21 | 17.37 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -6.90 | -3.76 | -7.29 |
| EPS (TTM) % | 23.76 | 10.68 | -17.55 |
| Dividend % | 26.80 | 8.24 | 4.86 |
Note: Units in Millions of US Dollars
Performance for AstraZeneca PLC
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 7.60 | 5.39 | 99 | 20 |
| 13 Week | 0.47 | -2.14 | 99 | 34 |
| 26 Week | 7.52 | 4.45 | 99 | 28 |
| 52 Week | 2.55 | -5.39 | 99 | 12 |
| YTD | 16.15 | 8.98 | 99 | 25 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- UPDATE 1-Moderna, largest biotech to go public, fails to impress in market debut
- Moderna, largest biotech to go public, fails to impress in market debut
- CORRECTED-UPDATE 1-AstraZeneca's Imfinzi fails to meet main goals in head and neck cancer study
- AstraZeneca's Imfinzi fails to meet main goals in head and neck cancer study
- UPDATE 1-UK Stocks-Factors to watch on Dec 7
Institutional Holders
| % Shares Owned: | 56.05% |
| # of Holders: | 577 |
| Total Shares Held: | 710,009,124 |
| 3 Mo. Net Change: | 8,433,381 |
| # New Positions: | 14 |
| # Closed Positions: | 33 |
| # Increased Positions: | 166 |
| # Reduced Positions: | 177 |
| # Net Buyers: | -11 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
- Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after today’s update?
- What does AstraZeneca plc's deal with Pfizer mean for shareholders?
- 3 stocks to help you retire early
- Is it time to take profits on GlaxoSmithKline plc and AstraZeneca plc?
- These FTSE 100 stars have exploded in Q3! And they're not finished yet
- Why now is the perfect time to buy these 3 super income stocks